Friedreich’s Ataxia – Epidemiology – Mature Markets
DRG Epidemiology's coverage of Friedreich's ataxia (FA) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of FA for each country as well as annualized case counts projected to the national population. DRG Epidemiology's FA forecast will answer the following questions:
- Of all people diagnosed with FA, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of FA over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following FA subpopulations:
- Diagnosed prevalence of FA by comorbid cardiomyopathy.
- Diagnosed prevalence of FA by comorbid diabetes.
Note: Coverage may vary by country.
Table of contents
- Friedreich's Ataxia - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Diagnosed Prevalence of Friedreich's Ataxia per 100,000 People of All Ages in 2020 and 2040
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Friedreich's Ataxia Over the Next 20 Years
- Epidemiology Data
- Methods
- Diagnosed Prevalence
- Diagnosed Prevalence by Comorbid Cardiomyopathy
- Diagnosed Prevalence by Comorbid Diabetes
- Drug-Treatable Cases
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Friedreich's Ataxia
- Studies Excluded from the Analysis of Friedreich's Ataxia
- Risk/Protective Factors
- Risk/Protective Factors for Friedreich's Ataxia
- Bibliography
- Glossary
- Literature Review
- Introduction
Mike Hughes, M.Sc., Ph.D., is the director of the Epidemiology department at DRG, part of Clarivate. He joined DRG in 2006 and has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis, and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He also helped develop national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke, and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in noncommunicable epidemiology. Dr. Hughes received his Ph.D. in risk modeling in intensive care in 2003 from City University, London, and his Ph.D. in statistical causation and foundations of probability theory from the University of Nottingham.
Mariam Sophia, M.P.H., Epidemiologist. Prior to studying epidemiology, she had a private clinical practice and later worked as a tutor at Manipal College of Dental Sciences. She has experience working in COVID-19 care centers and in Tele ICU. She holds an M.P.H. from India’s Manipal University, where she specialized in epidemiology. Her research thesis assessed the nutritional status of tribal children less than five years old. She has interned in the government-run tuberculosis program (RNTCP).